Interim Phase 2 Survival Data for PV-10 Will Be Presented by Professor John F. Thompson, MD, on November 21, 2009

Lead Investigator for Provectus' PV-10 Trial Will Present At
3rdWorld Meeting of Interdisciplinary
Melanoma/Skin Cancer Centers in Berlin

Will Update Compassionate Use Program

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Nov 17, 2009 - Provectus
Pharmaceuticals, Inc. (OTC BB: PVCT), a development-stage oncology
and dermatology biopharmaceutical company, announced today that
Professor John F. Thompson, MD, Professor of Melanoma and Surgical
Oncology at the University of Sydney, Director of the Melanoma
Institute Australia, and Lead Investigator of the Phase 2 study of
PV-10 for Metastatic Melanoma, will be presenting data at the
3rd World Meeting of Interdisciplinary Melanoma/Skin
Cancer Centers on November 21, 2009 in Berlin, Germany.

In his presentation entitled “PV-10 in the Local Treatment
of Melanoma Metastasis,” Professor Thompson will be
presenting overall survival data for the Phase 1 and Phase 2 trials
as well as an update on data from the expanded access use of PV-10
in Australia and the United States (“Compassionate
Use”). Provectus expects to issue a press release to update
shareholders and the medical and scientific community regarding the
data early next week after the completion of the presentation.

Craig Dees, PhD, CEO of Provectus said, “We are excited
about Professor Thompson's presentation, which will be the first
time that interim survival data for the Phase 2 trial will be
presented. Further, his discussion will provide the first look at
the progress that has been made with our expanded access program
for PV-10, the means through which certain qualified patients can
receive PV-10 on a compassionate use basis, in Australia and the
United States. Both of these aspects of his presentation are
certain to be very enlightening on the topic of PV-10's continued
development.”

About the 3rdWorld Meeting of
Interdisciplinary Melanoma/Skin Cancers

This meeting provides a unique opportunity for melanoma
clinicians and researchers, who are part of multidisciplinary
melanoma/skin cancer centers to interact, learn from one another,
establish collaborations and set an agenda for the further
evolution of multidisciplinary melanoma care and research. The
conference will feature Plenary Session and Symposia speakers who
are recognized experts in melanoma treatment and research.

About PV-10

PV-10 is a proprietary, injectable formulation of Rose Bengal, a
compound that has been in use for nearly thirty years by
ophthalmologists to assess damage to the eye. It has also been used
as an intravenous diagnostic to detect ailments of the liver. Rose
Bengal is a small molecule agent with an established safety
history, a short half-life in the bloodstream, and is excreted via
the liver and kidneys. Provectus has discovered a novel use for
Rose Bengal based on the observation that it is selectively toxic
to cancer calls via a process called chemoablation whereby cells
undergo a form of cell death that mimics both features of necrosis
and apoptosis.

Provectus Pharmaceuticals specializes in developing oncology and
dermatology therapies. Its lead oncology agent, PV-10, is designed
to selectively target and destroy cancer cells without harming
surrounding healthy tissue, significantly reducing systemic side
effects. Its oncology focus is on melanoma, breast cancer and
metastatic liver cancer. The Company has received orphan drug
designation from the FDA for its melanoma indication. Its lead
dermatological drug, PH-10, also targets abnormal or diseased
cells, with the current focus on psoriasis and atopic dermatitis.
Provectus has recently completed enrollment in three of its Phase 2
trials -- PV-10 as a therapy for metastatic melanoma, and PH-10 as
a topical treatment for atopic dermatitis and for psoriasis. It has
also recently initiated a Phase 1 trial for PV-10 for liver cancer.
Information about these and the Company's other clinical trials can
be found at the NIH registry,
www.clinicaltrials.gov. For additional information about
Provectus please visit the Company's website at
www.pvct.com or contact Porter, LeVay & Rose, Inc.

FORWARD-LOOKING STATEMENTS: The forward-looking statements
contained herein are subject to certain risks and uncertainties
that could cause actual results to differ materially from those
reflected in the forward-looking statements. Readers are cautioned
not to place undue reliance on these forward-looking statements,
which reflect management's analysis only as of the date hereof. The
company undertakes no obligation to publicly revise these
forward-looking statements to reflect events or circumstances that
arise after the date thereof.

Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment.